Single-dose high-dose liposomal amphotericin B combination therapy,
does it really help with Noninferior 10-week all-cause mortality in HIV-associated cryptococcal meningitis?
research showsThe grade is B with 72 points. Ten-week all-cause mortality was 24.8% (101/407) with the single high-dose liposomal amphotericin B regimen and 28.7% (117/407) with standard amphotericin B deoxycholate, an absolute difference of -3.9 points. The upper one-sided 95% confidence limit was +1.2 points, within the prespecified +10-point noninferiority margin (P<0.001).
ads claimIt is supported to say that the single-dose AmBisome combination was noninferior for 10-week mortality. It is incorrect to say that one infusion completes treatment or that it significantly lowered mortality. Fourteen days of flucytosine and fluconazole and subsequent antifungal therapy were still required.
Useful facts when choosing a product
- The regimen used one 10 mg/kg intravenous AmBisome dose plus 14 days of flucytosine and fluconazole.
- Gilead Sciences donated AmBisome; investigators reported no company role in design, analysis, or manuscript preparation.
- This is hospital-based induction therapy for severe cryptococcal meningitis and requires specialist monitoring.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.high-dose-liposomal-amphotericin-b-combination-therapy.UNK.all-cause-mortality-in-hiv-associated-cryptococcal-meningitis.noninferior.activeUnknown > high-dose liposomal amphotericin B combination therapy > Unknown > all-cause mortality in HIV-associated cryptococcal meningitis > Noninferiority claim > Active comparator
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The trial randomized 844 adults with HIV-associated cryptococcal meningitis in five African countries and analyzed 814 in the prespecified population. The paper stated, "the trial was powered to show noninferiority at a 10-percentage-point margin." Mortality was 24.8% versus 28.7%, difference -3.9 points, upper limit +1.2 points. Complete-case and per-protocol analyses agreed.
Why this is classified as B (72)
This was a large randomized trial of actual 10-week mortality, and the result met the prespecified +10-point noninferiority margin. Lack of independent replication, the noninferiority design, and manufacturer provision of AmBisome give B with 72 points.
Counterpoint. The trial used specialist hospitals with access to combination antifungals and monitoring. The result cannot automatically be transferred to settings without flucytosine, inpatient support, or toxicity monitoring.
Rejudgment record. Primary paper, protocol, and registration checked — Large active-controlled noninferiority randomized trial of 10-week all-cause mortality
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferiority for 10-week all-cause mortality | B | The +1.2-point upper limit was within the prespecified +10-point margin. |
| Reduction in severe adverse events | B | Grade 3 or 4 events were 50.0% versus 62.3%. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Jarvis et al. AMBITION | Multicenter open-label active-controlled noninferiority randomized trial | 844 randomized, 814 in the prespecified analysis | EDCTP, SIDA, Wellcome/MRC/UKAID and others; Gilead supplied AmBisome | All-cause mortality at 10 weeks | 24.8% versus 28.7%, absolute difference -3.9 points, upper one-sided 95% CI +1.2 points; margin +10 points, P<0.001 | Large hard-outcome RCT; limited by noninferiority and supplied drug |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis - Benefit — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/single-dose-liposomal-amphotericin-b-cryptococcal-meningitis/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.